{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/shingles/management/management/","result":{"pageContext":{"chapter":{"id":"9872f447-6f59-502d-b6cb-a0fae6d2c085","slug":"management","fullItemName":"Scenario: Management","depth":2,"htmlHeader":"<!-- begin field 69b67572-b72c-414b-bce9-1118ff053769 --><h2>Scenario: Management</h2><!-- end field 69b67572-b72c-414b-bce9-1118ff053769 -->","summary":"Covers the management of people with shingles.","htmlStringContent":"<!-- begin item 61ac42e7-c851-47ee-86c5-6a8ff681c35b --><!-- begin field a2e9e8af-6a2b-4332-b2d2-acbc0158e4db --><p>From age 12 months onwards.</p><!-- end field a2e9e8af-6a2b-4332-b2d2-acbc0158e4db --><!-- end item 61ac42e7-c851-47ee-86c5-6a8ff681c35b -->","topic":{"id":"012e484d-8c14-5168-bb5d-e5acb7d4571a","topicId":"2969a8ac-cb7f-4569-be79-822e6009081a","topicName":"Shingles","slug":"shingles","lastRevised":"Last revised in October 2020","chapters":[{"id":"eeb1b918-6c05-5340-b348-ce2809516623","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"8ad8b1b2-36bb-5262-ab5a-05763d6e4c7d","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"b1aed669-8481-5315-ab58-4bb18606e360","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"8fef2c66-91dc-57c6-8cd3-4e4eff8d7727","slug":"changes","fullItemName":"Changes"},{"id":"ea603e45-ec07-5201-a182-ebef4c48ef6b","slug":"update","fullItemName":"Update"}]},{"id":"81feec28-1a5d-5a24-9c52-bee13821b03b","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"bb672f83-c2bd-5dd7-9934-78f09729db48","slug":"goals","fullItemName":"Goals"},{"id":"2036bd3f-37bc-5cea-887d-55c3fc68c7cf","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"cc04b460-a0d8-5e8d-b8d0-c044947b4bd6","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"ee3573cb-38d5-5d4c-9c9d-cd274242d964","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"52999d3b-9cce-59c5-b588-1f7ad7de33e2","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"40a91fd6-3c01-5713-85ad-0a5c4379eab9","slug":"nice-quality-standards","fullItemName":"NICE Quality standards"}]},{"id":"04a0af22-814d-5b14-b28c-7916f1772a4d","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"097dfec6-754a-54a8-9d96-44e1c5704248","slug":"definition","fullItemName":"Definition"},{"id":"f20034b1-ae3e-505b-ac16-3e11f2a6653e","slug":"prevalence","fullItemName":"Prevalence"},{"id":"e92f0243-b1ac-50d9-a31a-a07a4c61c5a7","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"b6f8c581-b332-5d26-ba45-ccfb7189a387","slug":"complications","fullItemName":"Complications"},{"id":"012c8f32-e9cf-5897-a695-4c21cd28ae5d","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"81f3feff-d640-5ee2-83fa-af1a4e8b586a","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"56b89dcf-d466-50f3-a8a0-3a9477ef3362","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"01bc96b7-ea05-59b9-963a-16b2722b9367","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"acd9aec2-87d6-5084-bd3a-5c0b1d164ab4","fullItemName":"Management","slug":"management","subChapters":[{"id":"9872f447-6f59-502d-b6cb-a0fae6d2c085","slug":"management","fullItemName":"Scenario: Management"},{"id":"9ecdcc36-4fec-5b60-aa42-2032f2c406a4","slug":"prevention","fullItemName":"Scenario: Prevention"}]},{"id":"929d18e1-e1f0-5d08-8c55-d289b349a9fd","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"4445c1da-4f7a-5f12-a909-0112bbd72453","slug":"antiviral-drugs","fullItemName":"Antiviral drugs"},{"id":"1223613b-f5a6-5da6-a311-275f5d6181b2","slug":"zostavax","fullItemName":"Zostavax"}]},{"id":"67979756-a00f-5f10-a93e-81509b35e1a8","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"625749c2-4e09-57ba-bdee-cd206d8b02d5","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"377ce207-6229-5548-aef7-a637f176a94e","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"19ac0831-d4e2-52c3-b127-e78b1f26fb6f","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"d46d7aff-a113-50d5-afa1-3310aad844d7","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"d23205e9-41c9-5c70-a9f9-5ce3cfae633a","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"cf98894b-c083-59fd-8150-f390845960f1","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"a52b727c-ba28-5973-9e3c-e4882a883593","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"acd9aec2-87d6-5084-bd3a-5c0b1d164ab4","slug":"management","fullItemName":"Management"},"subChapters":[{"id":"17ce5f35-5636-5264-8d2c-9cd2574c2ba2","slug":"general-management","fullItemName":"General management","depth":3,"htmlHeader":"<!-- begin field e23ecc00-851f-4346-9827-7aabf36e4a4b --><h3>How should I manage a person with shingles?</h3><!-- end field e23ecc00-851f-4346-9827-7aabf36e4a4b -->","summary":null,"htmlStringContent":"<!-- begin item 1992e042-c129-4cf0-89c9-6596d7bed4cb --><!-- begin field 909342c8-ced2-47e8-a972-7708af3218d3 --><ul><li><strong>Assess:</strong><ul><li>The severity of symptoms.<ul><li>Consider assessing pain intensity using a validated pain assessment scale, such as the Visual Analog Scale. </li><li>Note that in immunocompromised people, rash may be severe, long-lasting, or affect multiple dermatomes.  </li></ul></li><li>For possible <a class=\"topic-reference internal-reference\" href=\"/topics/shingles/background-information/complications/\">complications</a> of shingles, such as infection and ocular complications.</li><li>For <a class=\"topic-reference internal-reference\" href=\"/topics/shingles/background-information/risk-factors/\">risk factors</a> for complications, such as long-term corticosteroid use and shingles of the head and/or neck area.</li></ul></li><li><strong>Admit to hospital (or seek immediate specialist advice) if: </strong><ul><li>Serious <a class=\"topic-reference internal-reference\" href=\"/topics/shingles/background-information/complications/\">complications</a> (such as meningitis, encephalitis, or myelitis) are suspected.</li><li>The person has shingles in the ophthalmic distribution of the trigeminal nerve, especially those with:<ul><li>Hutchinson's sign — a rash on the tip, side, or root of the nose, representing the dermatome of the nasociliary nerve, which is a prognostic factor for subsequent eye inflammation and permanent corneal denervation.</li><li>Visual symptoms.</li><li>An unexplained red eye.</li></ul></li><li>A severely immunocompromised person has shingles, or an immunocompromised person has shingles where the rash is severe, widespread, or they are systemically unwell.</li><li>An immunocompromised child has shingles.</li></ul></li><li><strong>For all other people with shingles:</strong><ul><li>Consider the need for oral antiviral treatment. See the section on <a class=\"topic-reference internal-reference\" href=\"/topics/shingles/management/management/#antiviral-treatment\">Antiviral treatment</a> for more information.</li><li>Manage pain. See the section on <a class=\"topic-reference internal-reference\" href=\"/topics/shingles/management/management/#pain-management\">Pain management</a> for more information.</li><li>Give appropriate information and advice. See the section on <a class=\"topic-reference internal-reference\" href=\"/topics/shingles/management/management/#information-advice\">Information and advice</a> for more information.</li><li>Refer, or seek specialist advice, if:<ul><li>New vesicles are forming after 7 days of <a class=\"topic-reference internal-reference\" href=\"/topics/shingles/management/management/#antiviral-treatment\">oral antiviral treatment</a>, or healing is delayed.</li><li>A person who is thought to be immunocompetent has had two episodes of shingles.</li><li>Shingles recurs in an immunocompromised person — long-term prophylaxis to prevent recurrence of uncomplicated shingles is not routinely recommended, but may be useful for some people.</li><li>Pain is inadequately controlled by <a class=\"topic-reference internal-reference\" href=\"/topics/shingles/management/management/#pain-management\">oral analgesia</a>, or a strong opioid (such as morphine) is being considered.</li></ul></li></ul></li><li><strong>Use clinical judgment to decide who to consult or refer to (for example ophthalmology, dermatology, obstetrics, immunology, or pain specialist, depending on the presenting problem) and the urgency, depending on the risk to the person and their clinical condition.</strong></li></ul><!-- end field 909342c8-ced2-47e8-a972-7708af3218d3 --><!-- end item 1992e042-c129-4cf0-89c9-6596d7bed4cb -->","subChapters":[{"id":"fdfc057e-2d75-504f-a09b-e7e8c797c58b","slug":"basis-for-recommendation-0be","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 78e69116-bf9b-433f-b803-011d11c21475 --><h4>Basis for recommendation</h4><!-- end field 78e69116-bf9b-433f-b803-011d11c21475 -->","summary":null,"htmlStringContent":"<!-- begin item 0be5a133-41cc-4842-a3d4-f7e75fd35281 --><!-- begin field 758e836e-43dc-4f81-9741-7691d7992b6a --><p>These recommendations are largely based on the Primary Care Dermatology Society (PCDS) guideline <em>Herpes zoster (syn. shingles)</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">PCDS, 2017</a>], the <em>European consensus‐based (S2k) Guideline on the Management of Herpes Zoster – guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV), Part 2: Treatment</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">Werner, 2017b</a>], the British National Formulary (BNF) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">Joint Formulary Committee, 2019</a>], the UK Teratology Information Service (UKTIS) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">UKTIS, 2018</a>], a database on the use of drugs in breastfeeding women [<a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">LactMed, 2018a</a>], the manufacturers' Summaries of Product Characteristics (SPCs) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">ABPI, 2018a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">ABPI, 2018b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">ABPI, 2019a</a>], and on expert opinion in review articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">Ahmed et al, 2007</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">Dworkin et al, 2007</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">Rashid et al, 2007</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">Schmader, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">Saguil, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">BMJ, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">Le, 2019</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">Ting, 2019</a>].</p><h5>Assessing the person</h5><ul><li>This recommendation is based on what CKS considers to be good clinical practice and is in line with recommendations in the European Guideline<em> </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">Werner, 2017a</a>]. A thorough assessment is needed to help decide whether to admit, refer, or seek specialist advice, or whether the person can be safely managed in primary care. </li></ul><h5>When to admit or seek immediate specialist advice </h5><ul><li><strong>People with serious complications</strong><ul><li>This recommendation is based on what CKS considers to be good clinical practice.</li></ul></li><li><strong>People with eye involvment</strong><ul><li><a class=\"topic-reference internal-reference\" href=\"/topics/shingles/background-information/complications/\">Herpes zoster ophthalmicus</a> is potentially serious and may result in severe and lasting pain, particularly in elderly people. Without antiviral treatment, about 50% of people will develop various eye disorders, some of which may be severe [<a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">PCDS, 2017</a>].</li><li>Most ocular complications can be managed in the outpatient setting, except for acute retinal necrosis (the most serious and blinding complication), which requires hospital admission for immediate intravenous and intravitreal antiviral treatment [<a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">Ting, 2019</a>].</li></ul></li><li><strong>Immunocompromised people</strong><ul><li>The recommendation to admit or seek immediate specialist advice for severely immunocompromised people, immunocompromised children, or immunocompromised people with a widespread rash or who are systemically unwell is based on expert opinion in review articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">BMJ, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">Le, 2019</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">Ting, 2019</a>].<ul><li>Shingles is more common and often more complicated in immunocompromised people, and treatment aims to reduce life-threatening complications by decreasing skin and visceral dissemination [<a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">BMJ, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">Le, 2019</a>].</li><li>Intravenous antiviral treatment is usually indicated in people with disseminated infection or severe immunosuppression [<a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">BMJ, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">Le, 2019</a>].</li></ul></li></ul></li></ul><h5>Considering the need for oral antiviral treatment</h5><ul><li>See the section on <a class=\"topic-reference internal-reference\" href=\"/topics/shingles/management/management/#antiviral-treatment\">Antiviral treatment</a> for more information.</li></ul><h5>Managing pain </h5><ul><li>See the section on <a class=\"topic-reference internal-reference\" href=\"/topics/shingles/management/management/#pain-management\">Managing pain</a> for more information.</li></ul><h5>Giving appropriate information and advice</h5><ul><li>See the section on <a class=\"topic-reference internal-reference\" href=\"/topics/shingles/management/management/#information-advice\">Information and advice</a> for more information.</li></ul><h5>When to refer</h5><ul><li><strong>New vesicles forming after 7 days of antiviral treatment</strong><ul><li>This recommendation is based on expert opinion that the appearance of new vesicles for more than one week increases suspicion of an underlying immunodeficiency syndrome [<a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">Dworkin et al, 2007</a>].</li></ul></li><li><strong>Recurrent shingles</strong><ul><li>CKS recommends referral of a person with a reactivation of shingles, as it is atypical to see reactivations in younger people with no history of malignancy and no immune deficit [<a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">Rashid et al, 2007</a>]; therefore, underlying immunocompromise may need to be excluded.</li><li>CKS recommends seeking specialist advice for recurrent shingles in immunocompromised people. Shingles typically recurs once prophylaxis is stopped in immunocompromised people, and recurrences are more likely to be associated with aciclovir-resistant strains [<a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">Ahmed et al, 2007</a>]. </li></ul></li><li><strong>Pain inadequately controlled or considering a strong opioid </strong><ul><li>This recommendation is based on what CKS considers to be good clinical practice.</li></ul></li></ul><!-- end field 758e836e-43dc-4f81-9741-7691d7992b6a --><!-- end item 0be5a133-41cc-4842-a3d4-f7e75fd35281 -->","subChapters":[]}]},{"id":"d6d1b56f-cf3c-5e2a-aa07-39cf11339f4d","slug":"antiviral-treatment","fullItemName":"Antiviral treatment","depth":3,"htmlHeader":"<!-- begin field e4a45003-5c48-4603-8063-e41ed289e716 --><h3>When should I prescribe oral antiviral treatment?</h3><!-- end field e4a45003-5c48-4603-8063-e41ed289e716 -->","summary":null,"htmlStringContent":"<!-- begin item ba225ace-e112-4369-9dfc-82139c41cccf --><!-- begin field ee0091e4-5f64-4ed3-97fd-0913f65484cb --><ul><li><strong>If admission or immediate specialist advice is not <a class=\"topic-reference internal-reference\" href=\"/topics/shingles/management/management/#general-management\">indicated</a>, c</strong><strong>onsider the need for oral antiviral treatment (aciclovir, valaciclovir, or famciclovir).</strong><ul><li><strong>Prescribe an oral antiviral treatment </strong>within 72 hours of rash onset for people with any of the following criteria:<ul><li>Immunocompromise (if the level of immunocompromise is not severe, the rash is localized, the person is not systemically unwell, and they can be closely followed up).</li><li>Non-truncal involvement (such as shingles affecting the neck, limbs, or perineum).</li><li>Moderate or severe pain.</li><li>Moderate or severe rash.</li></ul></li><li><strong>Consider prescribing oral antiviral treatment </strong>within 72 hours of rash onset for all people aged over 50 years to reduce the incidence of <a class=\"topic-reference internal-reference\" href=\"/topics/shingles/background-information/complications/\">post-herpetic neuralgia</a>, which is most common in this age group.</li><li>If it is not possible to initiate treatment within 72 hours, consider starting antiviral treatment up to one week after rash onset, especially if the person is at higher risk of severe shingles or complications (for example continued vesicle formation, older age, immunocompromised, or in severe pain). </li><li><strong>If a pregnant or breastfeeding woman has shingles,</strong> seek specialist advice before prescribing antiviral treatment.</li><li><strong>For immunocompetent children with shingles,</strong> antiviral treatment is not usually recommended.</li><li>See the prescribing information section on <a class=\"topic-reference internal-reference\" href=\"/topics/shingles/prescribing-information/antiviral-drugs/\">Antiviral drugs</a> for information on choice of treatment, recommended dosages, contraindications, cautions, drug interactions, and adverse effects.</li></ul></li><li><strong>Refer, or seek specialist advice, if:</strong><ul><li>New vesicles are forming after 7 days of antiviral treatment, or healing is delayed.</li></ul></li></ul><!-- end field ee0091e4-5f64-4ed3-97fd-0913f65484cb --><!-- end item ba225ace-e112-4369-9dfc-82139c41cccf -->","subChapters":[{"id":"6c4df357-9f19-5f94-b4db-d368d7842d2e","slug":"basis-for-recommendation-cfc","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 62f999ee-e5c4-40d0-b626-e9f4fb571077 --><h4>Basis for recommendation</h4><!-- end field 62f999ee-e5c4-40d0-b626-e9f4fb571077 -->","summary":null,"htmlStringContent":"<!-- begin item cfc780c8-af60-4c3f-a12b-04f0b921f394 --><!-- begin field 160d83c3-4a40-4692-845f-b949cf79a7b9 --><p>These recommendations are largely based on <em>Summary of antimicrobial prescribing guidance – managing common infections (September 2019)</em> published by the National Institute for Health and Care Excellence (NICE) and Public Health England (PHE) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">NICE and PHE, 2019</a>], <em>Summary of antimicrobial prescribing guidance – managing common infections: PHE context, references and rationales </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">PHE, 2019b</a>], the <em>European consensus‐based (S2k) Guideline on the Management of Herpes Zoster – guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV), Part 2: Treatment</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">Werner, 2017b</a>], trial evidence [<a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">Wood et al, 1996</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">Kurokawa, 2002</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">Chen et al, 2014</a>], the British National Formulary (BNF) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">Joint Formulary Committee, 2019</a>], the manufacturers' Summaries of Product Characteristics (SPCs) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">ABPI, 2018a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">ABPI, 2018b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">ABPI, 2019a</a>], and expert opinion in review articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">Dworkin et al, 2007</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">Cohen, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">Kim et al, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">Johnson et al, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">Saguil, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">Werner, 2017b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">BMJ, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">Le, 2019</a>].</p><h5>Prescribing an oral antiviral treatment </h5><ul><li>The aims of antiviral treatment in people with shingles are to reduce viral replication, hasten the healing of skin lesions and stop the formation of new ones, reduce the intensity and duration of pain, and reduce the risk of post-herpetic neuralgia and other complications [<a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">Cohen, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">Werner, 2017b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">BMJ, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">Le, 2019</a>]. </li><li>Aciclovir, famciclovir, and valaciclovir have been shown to be superior to placebo in reducing the duration of skin symptoms and the duration and severity of pain associated with shingles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">Wood et al, 1996</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">Dworkin et al, 2007</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">Werner, 2017b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">BMJ, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">Le, 2019</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">PHE, 2019b</a>].</li><li>Topical antiviral agents are ineffective for the treatment of herpes zoster and are not recommended [<a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">Cohen, 2013</a>].</li></ul><h5>Timing of the treatment</h5><ul><li>Antiviral treatment is most effective if initiated as soon as possible after the onset of the rash [<a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">Cohen, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">ABPI, 2018a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">ABPI, 2018b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">BMJ, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">ABPI, 2019a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">Le, 2019</a>]. However, treatment is still warranted outside the 72-hour window (up to 1 week after rash onset) if there is high risk of severe shingles or continued vesicle formation, in older age, in immunocompromised people, or if there is severe pain [<a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">Kurokawa, 2002</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">Saguil, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">NICE and PHE, 2019</a>].</li><li>Recommendations from an international panel of experts advise consideration of prescribing after 72 hours if the person is older or has severe pain, as these are strong risk factors for post-herpetic neuralgia [<a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">Dworkin et al, 2007</a>].</li></ul><h5>When to prescribe antiviral treatment </h5><ul><li>CKS recommends treating immunocompromised people with oral antivirals in primary care only if the person is not severely immunocompromised, the rash is localized and not severe, and the person can be closely followed up. This is based on an expert consensus document [<a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">Dworkin et al, 2007</a>] and on expert opinion in review articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">Ahmed et al, 2007</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">Kim et al, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">BMJ, 2018</a>]. Severely immunocompromised people require referral for intravenous antiviral treatment [<a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">BSSI, 1995</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">International Herpes Management Forum, 2002</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">Tyring, 2007</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">BMJ, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">Le, 2019</a>].</li><li>The recommendation to consider antiviral treatment in people with non-truncal involvement, or moderate to severe pain or rash is based on the NICE/PHE guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">NICE and PHE, 2019</a>] and the European guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">Werner, 2017b</a>].</li></ul><h5>Considering antiviral treatment for all people aged over 50 years to reduce the incidence of post-herpetic neuralgia</h5><ul><li>Based on historical evidence, experts generally recommend antiviral treatment for all people aged 50 years and over to reduce the incidence of post-herpetic neuralgia [<a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">Dworkin et al, 2007</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">Kim et al, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">Werner, 2017b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">BMJ, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">Le, 2019</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">NICE and PHE, 2019</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">PHE, 2019c</a>].</li><li>A Cochrane systematic review (search date: April 2013) that assessed the effectiveness of antiviral drugs in preventing post-herpetic neuralgia (n = 1211) concluded, on the basis of high-quality evidence, that oral aciclovir does not significantly reduce the incidence of post-herpetic neuralgia. There was no significant differences between aciclovir and placebo in the incidence of post-herpetic neuralgia 4 months after the onset of acute herpetic rash, or at 6 months. The authors found insufficient evidence from randomized controlled trials to ascertain whether this is also the case for other antivirals and discussed the need for more research in subgroups such as immunocompromised people [<a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">Chen et al, 2014</a>].</li><li>CKS therefore recommends considering oral antiviral treatment in this group of people, given the relatively low risk of complications associated with antiviral drugs [<a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">Werner, 2017b</a>].</li></ul><h5>Pregnant women</h5><ul><li>An analysis of the available evidence by the UKTIS found that data on outcomes other than congenital malformation in pregnant women with exposure to aciclovir was insufficient to exclude an increased risk. Use of valaciclovir did not suggest an increase in the risk of congenital malformation, although data were limited and did not assess other outcomes [<a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">UKTIS, 2018</a>].</li><li>In addition, the manufacturers of aciclovir, valaciclovir, and famciclovir recommend that they should only be used in pregnancy if the potential benefits of treatment outweigh the potential risks [<a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">ABPI, 2018a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">ABPI, 2018b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">ABPI, 2019a</a>].</li><li>CKS recommends seeking specialist advice before prescribing antiviral treatment to a pregnant woman.</li></ul><h5>Breastfeeding women</h5><ul><li>Aciclovir and valaciclovir are present at low concentrations in breastmilk and are not expected to adversely affect the infant [<a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">LactMed, 2018b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">LactMed, 2018c</a>].<strong> </strong>However, the BNF [<a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">Joint Formulary Committee, 2019</a>] and manufacturers advise using aciclovir and valaciclovir with caution in breastfeeding women [<a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">ABPI, 2018a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">ABPI, 2019a</a>].</li><li>There is no published experience with the use of famciclovir in breastfeeding women [<a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">LactMed, 2018a</a>]. The manufacturer recommends considering discontinuation of breast feeding if the woman's condition mandates treatment with famciclovir [<a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">ABPI, 2018b</a>]. </li><li>CKS recommends seeking specialist advice before prescribing antiviral treatment to a breastfeeding woman.</li></ul><h5>Immunocompetent children with shingles</h5><ul><li>CKS does not recommend antiviral treatment for otherwise healthy children because in this group shingles is usually mild [<a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">Feder and Hoss, 2004</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">Simon et al, 2010</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">Werner, 2017b</a>].</li><li>Expert opinion in the European guideline is that due to the lack of data on the safety in children, careful consideration of possible harms and benefits of an antiviral medication should be considered. The guideline suggests that [<a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">Werner, 2017b</a>]:<ul><li>In the absence of the risk of complications, antiviral treatment should not be used in children with shingles.</li><li>The initiation of an antiviral drug in children is suggested in the presence of risk factors for complicated courses of disease, if potential benefits outweigh the potential risks.</li></ul></li><li>Aciclovir, valaciclovir, and famciclovir are not licensed for treatment of herpes zoster in children [<a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">ABPI, 2018a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">ABPI, 2018b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">ABPI, 2019a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">Joint Formulary Committee, 2019</a>].</li></ul><h5>When to refer</h5><ul><li>This recommendation is based on expert opinion that the appearance of new vesicles for more than one week increases suspicion of an underlying immunodeficiency syndrome [<a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">Dworkin et al, 2007</a>].</li></ul><!-- end field 160d83c3-4a40-4692-845f-b949cf79a7b9 --><!-- end item cfc780c8-af60-4c3f-a12b-04f0b921f394 -->","subChapters":[]}]},{"id":"29f2b420-9974-570a-8bee-abb49e7a7a3c","slug":"pain-management","fullItemName":"Pain management","depth":3,"htmlHeader":"<!-- begin field b7f36b0c-b54b-49ac-ab9f-5fd77634fba7 --><h3>How should I manage the pain of shingles?</h3><!-- end field b7f36b0c-b54b-49ac-ab9f-5fd77634fba7 -->","summary":null,"htmlStringContent":"<!-- begin item 2217a0ec-f236-4491-b796-c300d74a84ad --><!-- begin field e3651cb9-6b26-42d1-b81a-f1b164724f63 --><ul><li><strong>For adults with </strong><strong>mild pain,</strong> offer a trial of paracetamol alone or in combination with codeine or a nonsteroidal anti-inflammatory drug (NSAID), such as ibuprofen.<ul><li>If this is not effective, or the person presents with severe pain, consider offering amitriptyline (off-label use), duloxetine (off-label use), gabapentin, or pregabalin. <ul><li>The choice of drug depends on the relative contraindications, possible drug interactions, and risk of adverse effects for each person. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/neuropathic-pain-drug-treatment/\">Neuropathic pain - drug treatment</a> for more information on choosing an appropriate treatment and for prescribing information.</li></ul></li><li>Consider oral corticosteroids in the first 2 weeks following rash onset in immunocompetent adults with localized shingles if pain is severe, but only in combination with antiviral treatment.<ul><li>Use clinical judgment, taking into account the risks and benefits of corticosteroid therapy for each person. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/corticosteroids-oral/\">Corticosteroids - oral</a> for information on prescribing oral corticosteroids.</li></ul></li><li>Seek specialist advice or refer to the pain team if:<ul><li>Pain is inadequately controlled by oral analgesia.</li><li>A strong opioid (such as morphine) is being considered.</li></ul></li><li>If there is persisting pain after the resolution of skin lesions, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/post-herpetic-neuralgia/\">Post-herpetic neuralgia</a> for management information.</li></ul></li><li><strong>For children with pain, </strong>offer a trial of paracetamol (avoid the use of NSAIDs). <ul><li>If this is not effective, seek specialist advice.</li></ul></li></ul><!-- end field e3651cb9-6b26-42d1-b81a-f1b164724f63 --><!-- end item 2217a0ec-f236-4491-b796-c300d74a84ad -->","subChapters":[{"id":"f1b7efd1-a73b-584c-8868-07e890767756","slug":"basis-for-recommendation-2df","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field d9653d8b-6581-4336-8dab-14e047848175 --><h4>Basis for recommendation</h4><!-- end field d9653d8b-6581-4336-8dab-14e047848175 -->","summary":null,"htmlStringContent":"<!-- begin item 2df7e2ca-cea7-4a44-a899-39b5a1003242 --><!-- begin field 7ec742ea-0ec7-4230-8d52-fbec9f7981c2 --><h5>Managing adults</h5><ul><li><strong>Simple analgesia</strong><ul><li>The recommendation to offer a trial of paracetamol alone or in combination with codeine or a nonsteroidal anti-inflammatory drug (NSAID) is based on expert opinion in review articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">Johnson et al, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">Schmader, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">BMJ, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">Le, 2019</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">Ting, 2019</a>] as CKS found no evidence from controlled trials for paracetamol, NSAIDs, codeine, or opioid analgesics for treating the pain of acute shingles.</li></ul></li><li><strong>Amitriptyline, duloxetine, gabapentin, or pregabalin</strong><ul><li>The recommendation to offer a choice of amitriptyline, duloxetine, gabapentin, or pregabalin is largely based on guidance in the National Institute for Health and Care Excellence (NICE) guideline <em>Neuropathic pain — pharmacological management. The pharmacological management of neuropathic pain in adults in non-specialist settings </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">NICE, 2013</a>] and is supported by expert opinion in review articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">Johnson et al, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">Schmader, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">Ting, 2019</a>]. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/neuropathic-pain-drug-treatment/\">Neuropathic pain - drug treatment</a> for more information.</li></ul></li><li><strong>Oral corticosteroids</strong><ul><li>Guidelines from the International Herpes Management Forum include considering the use of steroids to reduce the inflammation that may be contributing to acute pain [<a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">International Herpes Management Forum, 2002</a>]. This recommendation is supported by expert opinion in some review articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">Dworkin et al, 2007</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">Kim et al, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">Saguil, 2017</a>].</li><li>A review article on the presentation and management of shingles in older people states that the use of systemic corticosteroids to treat the acute pain of shingles is controversial, as this recommendation is often based on judgment and experience rather than on clinical evidence [<a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">Cohen, 2013</a>].</li><li>CKS identified two large randomized, double-blind, placebo-controlled studies that evaluated 21 days of corticosteroid treatment for the management of herpes zoster [<a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">Wood et al, 1994</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">Whitley et al, 1996</a>].<ul><li>One study [<a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">Wood et al, 1994</a>] found that people treated with corticosteroids and aciclovir had a greater reduction in pain on days 7 and 14, but on day 21 there was no difference.</li><li>The second study [<a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">Whitley et al, 1996</a>] found that corticosteroids combined with aciclovir did not affect cutaneous healing but did result in a significant benefit in quality of life on day 30, including less time returning to normal activity and uninterrupted sleep. Many people with chronic diseases, such as diabetes, renal insufficiency, and hypertension, were excluded, thereby limiting its applicability.</li></ul></li></ul></li><li><strong>Seeking specialist advice</strong><ul><li>The recommendation to seek specialist advice if pain is not adequately controlled by oral analgesia is based on what CKS considers to be good clinical practice.</li></ul></li></ul><h5>Managing children</h5><ul><li>These recommendations are pragmatic, based on what CKS considers to be good clinical practice.</li><li>CKS has not recommended the use of NSAIDs because of concerns that use of NSAIDs in children with varicella is associated with an increased risk of severe skin and soft tissue infections (usually caused by group A streptococcus and <em>Staphylococcus aureus) </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">UKMi, 2016</a>]. </li></ul><!-- end field 7ec742ea-0ec7-4230-8d52-fbec9f7981c2 --><!-- end item 2df7e2ca-cea7-4a44-a899-39b5a1003242 -->","subChapters":[]}]},{"id":"57eabc94-d977-5400-8d59-961c4dddfa7f","slug":"information-advice","fullItemName":"Information and advice","depth":3,"htmlHeader":"<!-- begin field e22563d5-6770-4ee7-92da-0f86d96d8c0a --><h3>What information and advice should I give a person with shingles?</h3><!-- end field e22563d5-6770-4ee7-92da-0f86d96d8c0a -->","summary":null,"htmlStringContent":"<!-- begin item 22034b36-0749-41f1-953f-3f128b89f80c --><!-- begin field 3593b4e4-85e1-4da5-9b7a-ea41cc924674 --><ul><li><strong>Explain that</strong> only a person who has not had chickenpox or the varicella vaccine can catch chickenpox from a person with shingles.<strong> </strong>The person with shingles is infectious until all the vesicles have crusted over (usually 5–7 days after rash onset).<strong> </strong></li><li><strong>Advise people with shingles to:</strong><ul><li>Avoid contact with people who have not had chickenpox, particularly pregnant women, immunocompromised people, and babies younger than 1 month of age. </li><li>Avoid sharing clothes and towels.</li><li>Wash their hands often.</li><li>Wear loose-fitting clothes to reduce irritation.</li><li>Cover lesions that are not under clothes while the rash is still weeping.</li><li>Avoid use of topical creams and adhesive dressings, as they can cause irritation and delay rash healing. </li><li>Keep the rash clean and dry to reduce the risk of bacterial superinfection. They should seek medical advice if there is an increase in temperature, as this may indicate bacterial infection.</li><li>Avoid work, school, or day care if the rash is weeping and cannot be covered. If the lesions have dried or the rash is covered, avoidance of these activities is not necessary. </li></ul></li><li><strong>Provide additional sources of information, advice, and support.</strong> <ul><li>The British Association of Dermatologists (BAD) has a patient information leaflet on <a data-hyperlink-id=\"5e21a322-23c4-4939-8ab6-aad400fae41a\" href=\"https://www.skinhealthinfo.org.uk/wp-content/uploads/2018/11/Shingles-Update-May-2016-lay-reviewed-May-20162.pdf\">Shingles (herpes zoster infection)</a>.</li><li>The NHS website has patient information on <a data-hyperlink-id=\"de7891ec-b125-4322-b06a-aad400fae432\" href=\"https://www.nhs.uk/conditions/shingles/\">Shingles</a>.</li><li>The <a data-hyperlink-id=\"8650b03a-b0ea-4b75-9e32-aad400fae44f\" href=\"https://shinglessupport.org.uk/\">Shingles Support Society</a> has information on <a data-hyperlink-id=\"60edb28c-11b3-4169-8e79-aad400fae47f\" href=\"https://shinglessupport.org.uk/frequently-asked-questions-about-shingles/\">Shingles</a> and <a data-hyperlink-id=\"1087f145-1819-4a5e-89dc-aad400fae492\" href=\"https://shinglessupport.org.uk/frequently-asked-questions-about-post-herpetic-neuralgia-phn/\">Postherpetic neuralgia</a>.</li></ul></li></ul><!-- end field 3593b4e4-85e1-4da5-9b7a-ea41cc924674 --><!-- end item 22034b36-0749-41f1-953f-3f128b89f80c -->","subChapters":[{"id":"d48ccadd-dc83-5a64-bdcb-c5c07b8f33b4","slug":"basis-for-recommendation-7df","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field c2085615-8bce-4bcd-b5aa-268f24e35504 --><h4>Basis for recommendation</h4><!-- end field c2085615-8bce-4bcd-b5aa-268f24e35504 -->","summary":null,"htmlStringContent":"<!-- begin item 7df0440d-5359-49c4-bc1c-47d879318157 --><!-- begin field 5bd9a120-9a2a-41db-8074-dcf27472cf97 --><p>These recommendations are based on the chapter on <em>Shingles (herpes zoster)</em> in <em>Immunisation against infectious disease</em> (the 'Green book'), published by Public Health England (PHE) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">PHE, 2016</a>], the Primary Care Dermatology Society (PCDS) guideline <em>Herpes zoster (syn. shingles)</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">PCDS, 2017</a>], the Centers for Disease Control and Prevention (CDC) guideline <em>Shingles (Herpes Zoster) </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">CDC, 2019</a>], and on expert opinion in review articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">Wilson, 2007</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">Gould, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">Schmader, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">BMJ, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">Le, 2019</a>]. </p><!-- end field 5bd9a120-9a2a-41db-8074-dcf27472cf97 --><!-- end item 7df0440d-5359-49c4-bc1c-47d879318157 -->","subChapters":[]}]}]}}},"staticQueryHashes":["3666801979"]}